FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980476255> ?p ?o ?g. }

• W2980476255 endingPage "2296" @default.
• W2980476255 startingPage "2283" @default.
• W2980476255 abstract "Chronic obstructive pulmonary disease (COPD) is a common condition responsible for substantial morbidity, mortality, and costs in the United States. The economic burden of COPD is driven primarily by hospitalizations, with 1 in 5 hospitalized patients experiencing a 30-day readmission. Bronchodilators, delivered via handheld inhalers or nebulizers, are the mainstay of therapy for COPD. However, differences in outcomes between short- and long-acting therapies are unclear. We examined real-world differences in 30-day readmission and exacerbation rates between Medicare beneficiaries with COPD treated with a nebulized long-acting beta2-agonist (arformoterol tartrate [ARF]) and beneficiaries treated with a nebulized short-acting beta2-agonist (SABA) for maintenance therapy after hospital discharge.Truven MarketScan Hospital Drug Database and Medicare files were probabilistically matched between 2009 and 2013 to identify beneficiaries who were aged ≥65 years and discharged from a hospital with a primary COPD diagnosis or a secondary COPD diagnosis and a primary diagnosis for another respiratory condition. Matching was performed by using COPD hospitalization date (±7 days) and source, length of stay (±1 day), discharge date and destination, and hospital region. After applying additional inclusion/exclusion criteria, 2 cohorts were created: nebulized ARF users (n = 953) and nebulized SABA users (n = 6939). Logistic regression analyses were used to examine 30-day readmission (all-cause and COPD related) and exacerbation rates. Odds ratios (ORs), 95% CIs, and P values were computed.On average, nebulized SABA users had more comorbidities than nebulized ARF users, including diabetes, atrial fibrillation, renal disease, musculoskeletal disease, myocardial infarction, and cognitive impairment (all, P < 0.0001). However, nebulized ARF users had a higher average COPD severity score than nebulized SABA users (49.5 v. 38.0; P < 0.001). COPD therapies at baseline were similar in both cohorts and included systemic corticosteroids (≥65%), short-acting bronchodilators (≥33%), and inhaled corticosteroids + long-acting beta2-agonists (30%). After adjusting for sociodemographic and hospital characteristics, concomitant medications, and case-mix, nebulized ARF users had 27% lower odds of an all-cause readmission (OR, 0.73; 95% CI, 0.59-0.92; P = 0.008) and 23% lower odds of a COPD-related readmission (OR, 0.77; 95% CI, 0.60-0.98; P = 0.032) at 30 days compared with users of a nebulized SABA. No difference was found in 30-day exacerbation rates between the cohorts.Nebulized ARF users had lower 30-day readmission rates, greater COPD severity, and fewer comorbidities than nebulized SABA users. In this population, maintenance treatment with ARF reduced costly COPD outcomes." @default.
• W2980476255 created "2019-10-25" @default.
• W2980476255 creator A5011438418 @default.
• W2980476255 creator A5030439581 @default.
• W2980476255 creator A5043925265 @default.
• W2980476255 creator A5089946954 @default.
• W2980476255 date "2019-11-01" @default.
• W2980476255 modified "2023-10-17" @default.
• W2980476255 title "Reduction in Hospital Readmission Rates Among Medicare Beneficiaries With Chronic Obstructive Pulmonary Disease: A Real-world Outcomes Study of Nebulized Bronchodilators" @default.
• W2980476255 cites W1877054624 @default.
• W2980476255 cites W1976280223 @default.
• W2980476255 cites W1980221743 @default.
• W2980476255 cites W1991296122 @default.
• W2980476255 cites W2021331487 @default.
• W2980476255 cites W2031162656 @default.
• W2980476255 cites W2036278969 @default.
• W2980476255 cites W2050126757 @default.
• W2980476255 cites W2050325691 @default.
• W2980476255 cites W2061326496 @default.
• W2980476255 cites W2075709422 @default.
• W2980476255 cites W2110548428 @default.
• W2980476255 cites W2120613741 @default.
• W2980476255 cites W2125522165 @default.
• W2980476255 cites W2129407162 @default.
• W2980476255 cites W2134054594 @default.
• W2980476255 cites W2138566131 @default.
• W2980476255 cites W2170131723 @default.
• W2980476255 cites W2309139110 @default.
• W2980476255 cites W2346408851 @default.
• W2980476255 cites W2403339270 @default.
• W2980476255 cites W2552207502 @default.
• W2980476255 cites W2594755499 @default.
• W2980476255 cites W2737733674 @default.
• W2980476255 cites W2765909374 @default.
• W2980476255 cites W2768857936 @default.
• W2980476255 cites W2792775847 @default.
• W2980476255 cites W2794019240 @default.
• W2980476255 cites W2795842221 @default.
• W2980476255 cites W2888346500 @default.
• W2980476255 cites W2902855073 @default.
• W2980476255 cites W1673296306 @default.
• W2980476255 doi "https://doi.org/10.1016/j.clinthera.2019.09.001" @default.
• W2980476255 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31630815" @default.
• W2980476255 hasPublicationYear "2019" @default.
• W2980476255 type Work @default.
• W2980476255 sameAs 2980476255 @default.
• W2980476255 citedByCount "4" @default.
• W2980476255 countsByYear W29804762552021 @default.
• W2980476255 countsByYear W29804762552022 @default.
• W2980476255 crossrefType "journal-article" @default.
• W2980476255 hasAuthorship W2980476255A5011438418 @default.
• W2980476255 hasAuthorship W2980476255A5030439581 @default.
• W2980476255 hasAuthorship W2980476255A5043925265 @default.
• W2980476255 hasAuthorship W2980476255A5089946954 @default.
• W2980476255 hasBestOaLocation W29804762551 @default.
• W2980476255 hasConcept C126322002 @default.
• W2980476255 hasConcept C134018914 @default.
• W2980476255 hasConcept C151956035 @default.
• W2980476255 hasConcept C156957248 @default.
• W2980476255 hasConcept C177713679 @default.
• W2980476255 hasConcept C194828623 @default.
• W2980476255 hasConcept C2776780178 @default.
• W2980476255 hasConcept C2777014857 @default.
• W2980476255 hasConcept C555293320 @default.
• W2980476255 hasConcept C71924100 @default.
• W2980476255 hasConceptScore W2980476255C126322002 @default.
• W2980476255 hasConceptScore W2980476255C134018914 @default.
• W2980476255 hasConceptScore W2980476255C151956035 @default.
• W2980476255 hasConceptScore W2980476255C156957248 @default.
• W2980476255 hasConceptScore W2980476255C177713679 @default.
• W2980476255 hasConceptScore W2980476255C194828623 @default.
• W2980476255 hasConceptScore W2980476255C2776780178 @default.
• W2980476255 hasConceptScore W2980476255C2777014857 @default.
• W2980476255 hasConceptScore W2980476255C555293320 @default.
• W2980476255 hasConceptScore W2980476255C71924100 @default.
• W2980476255 hasFunder F4320311407 @default.
• W2980476255 hasIssue "11" @default.
• W2980476255 hasLocation W29804762551 @default.
• W2980476255 hasLocation W29804762552 @default.
• W2980476255 hasOpenAccess W2980476255 @default.
• W2980476255 hasPrimaryLocation W29804762551 @default.
• W2980476255 hasRelatedWork W1974526650 @default.
• W2980476255 hasRelatedWork W2069826751 @default.
• W2980476255 hasRelatedWork W2077638660 @default.
• W2980476255 hasRelatedWork W2110152822 @default.
• W2980476255 hasRelatedWork W2265924223 @default.
• W2980476255 hasRelatedWork W2409754429 @default.
• W2980476255 hasRelatedWork W2552520857 @default.
• W2980476255 hasRelatedWork W2779821228 @default.
• W2980476255 hasRelatedWork W3016900151 @default.
• W2980476255 hasRelatedWork W2127760953 @default.
• W2980476255 hasVolume "41" @default.
• W2980476255 isParatext "false" @default.
• W2980476255 isRetracted "false" @default.
• W2980476255 magId "2980476255" @default.
• W2980476255 workType "article" @default.